Cipralisant

Cipralisant is a histamine antagonist that was developed by Sanofi-Aventis. It acts as an inverse agonist at the H3 receptor, and has stimulant and nootropic effects. Cipralisant was in clinical trials for the treatment of obesity and ADHD, but as of 2016, it is no longer under development.

Etymology

The name "Cipralisant" is derived from the name of the pharmaceutical company that developed it, Sanofi-Aventis, and the class of drugs it belongs to, histamine antagonists.

Pharmacology

Cipralisant is a selective H3 receptor inverse agonist. This means it binds to the H3 receptor and produces an effect opposite to that of an agonist. In the case of Cipralisant, this results in increased release of histamine, a neurotransmitter involved in regulating wakefulness and attention.

Clinical Trials

Cipralisant was in clinical trials for the treatment of obesity and ADHD. The drug showed promise in early trials, with patients showing improved cognitive function and weight loss. However, the development of the drug was discontinued for unknown reasons.

Related Terms

• Histamine antagonist
• Inverse agonist
• H3 receptor
• Stimulant
• Nootropic
• Clinical trials
• Obesity
• ADHD
• Sanofi-Aventis

See Also

• Histamine
• Neurotransmitter
• Wakefulness
• Attention
• Cognitive function
• Weight loss

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia